and M.W., the Merit Review Award (2I01BX004371) to M.W., and the South FL VA Foundation Research & Education fund to A.V.S
Due to its relatively short half-life, many research protocols split the total daily dose into two smaller administrations (e.g., morning and evening)
With expert oversight and custom protocols, Audra Foster, N.D
Evidence Quality Summary The honest assessment: mechanistic data is compelling, animal data is supportive, and human data exists but is not conclusive for GHK-Cu alone
A method of reversing, ameliroating or slowing progression of at least one symptom of Parkinson's disease in a patient in need thereof, comprising the step of administering to said patient an amount of one or more hepatocyte growth factor mimics sufficient to reverse, ameliorate or slow progression of said at least one symptom of Parkinson's disease, said one or more hepatocyte growth factor mimics having a general structural formula 1 2 3 wherein Ri is one of an N-acyl group, a substituted or unsubstituted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine